Promoting activity of (α4)3(β2)2 nicotinic cholinergic receptors reduces ethanol consumption

Jingyi Wang, Angelo Blasio, Holly L. Chapman, Christelle Doebelin, Victor Liaw, Alexander Kuryatov, Simone M. Giovanetti, Jon Lindstrom, Li Lin, Michael D. Cameron, Theodore M. Kamenecka, Matthew B. Pomrenze, Robert O. Messing

Research output: Contribution to journalArticle

Abstract

There is increasing interest in developing drugs that act at α4β2 nicotinic acetylcholine receptors (nAChRs) to treat alcohol use disorder. The smoking cessation agent varenicline, a partial agonist of α4β2 nAChRs, reduces alcohol intake, but its use can be limited by side effects at high therapeutic doses. There are two stoichiometric forms of α4β2 nAChRs, (α4)3(β2)2 and (α4)2(β2)3. Here we investigated the hypothesis that NS9283, a positive allosteric modulator selective for the (α4)3(β2)2 form, reduces ethanol consumption. NS9283 increased the potency of varenicline to activate and desensitize (α4)3(β2)2 nAChRs in vitro without affecting other known targets of varenicline. In male and female C57BL/6J mice, NS9283 (10 mg/kg) reduced ethanol intake in a two-bottle choice, intermittent drinking procedure without affecting saccharin intake, ethanol-induced incoordination or ethanol-induced loss of the righting reflex. Subthreshold doses of NS9283 (2.5 mg/kg) plus varenicline (0.1 mg/kg) synergistically reduced ethanol intake in both sexes. Finally, despite having no aversive valence of its own, NS9283 enhanced ethanol-conditioned place aversion. We conclude that compounds targeting the (α4)3(β2)2 subtype of nAChRs can reduce alcohol consumption, and when administered in combination with varenicline, may allow use of lower varenicline doses to decrease varenicline side effects.

Original languageEnglish (US)
Pages (from-to)301-308
Number of pages8
JournalNeuropsychopharmacology
Volume45
Issue number2
DOIs
StatePublished - Jan 1 2020

Fingerprint

Nicotinic Receptors
Cholinergic Receptors
Ethanol
Alcohols
Righting Reflex
Saccharin
Smoking Cessation
Ataxia
Varenicline
Inbred C57BL Mouse
Alcohol Drinking
Drinking
3-(3-(pyridine-3-yl)-1,2,4-oxadiazol-5-yl)benzonitrile
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Promoting activity of (α4)3(β2)2 nicotinic cholinergic receptors reduces ethanol consumption. / Wang, Jingyi; Blasio, Angelo; Chapman, Holly L.; Doebelin, Christelle; Liaw, Victor; Kuryatov, Alexander; Giovanetti, Simone M.; Lindstrom, Jon; Lin, Li; Cameron, Michael D.; Kamenecka, Theodore M.; Pomrenze, Matthew B.; Messing, Robert O.

In: Neuropsychopharmacology, Vol. 45, No. 2, 01.01.2020, p. 301-308.

Research output: Contribution to journalArticle

Wang, J, Blasio, A, Chapman, HL, Doebelin, C, Liaw, V, Kuryatov, A, Giovanetti, SM, Lindstrom, J, Lin, L, Cameron, MD, Kamenecka, TM, Pomrenze, MB & Messing, RO 2020, 'Promoting activity of (α4)3(β2)2 nicotinic cholinergic receptors reduces ethanol consumption', Neuropsychopharmacology, vol. 45, no. 2, pp. 301-308. https://doi.org/10.1038/s41386-019-0475-8
Wang, Jingyi ; Blasio, Angelo ; Chapman, Holly L. ; Doebelin, Christelle ; Liaw, Victor ; Kuryatov, Alexander ; Giovanetti, Simone M. ; Lindstrom, Jon ; Lin, Li ; Cameron, Michael D. ; Kamenecka, Theodore M. ; Pomrenze, Matthew B. ; Messing, Robert O. / Promoting activity of (α4)3(β2)2 nicotinic cholinergic receptors reduces ethanol consumption. In: Neuropsychopharmacology. 2020 ; Vol. 45, No. 2. pp. 301-308.
@article{8dc7134438164616a9577df9fc867ee6,
title = "Promoting activity of (α4)3(β2)2 nicotinic cholinergic receptors reduces ethanol consumption",
abstract = "There is increasing interest in developing drugs that act at α4β2 nicotinic acetylcholine receptors (nAChRs) to treat alcohol use disorder. The smoking cessation agent varenicline, a partial agonist of α4β2 nAChRs, reduces alcohol intake, but its use can be limited by side effects at high therapeutic doses. There are two stoichiometric forms of α4β2 nAChRs, (α4)3(β2)2 and (α4)2(β2)3. Here we investigated the hypothesis that NS9283, a positive allosteric modulator selective for the (α4)3(β2)2 form, reduces ethanol consumption. NS9283 increased the potency of varenicline to activate and desensitize (α4)3(β2)2 nAChRs in vitro without affecting other known targets of varenicline. In male and female C57BL/6J mice, NS9283 (10 mg/kg) reduced ethanol intake in a two-bottle choice, intermittent drinking procedure without affecting saccharin intake, ethanol-induced incoordination or ethanol-induced loss of the righting reflex. Subthreshold doses of NS9283 (2.5 mg/kg) plus varenicline (0.1 mg/kg) synergistically reduced ethanol intake in both sexes. Finally, despite having no aversive valence of its own, NS9283 enhanced ethanol-conditioned place aversion. We conclude that compounds targeting the (α4)3(β2)2 subtype of nAChRs can reduce alcohol consumption, and when administered in combination with varenicline, may allow use of lower varenicline doses to decrease varenicline side effects.",
author = "Jingyi Wang and Angelo Blasio and Chapman, {Holly L.} and Christelle Doebelin and Victor Liaw and Alexander Kuryatov and Giovanetti, {Simone M.} and Jon Lindstrom and Li Lin and Cameron, {Michael D.} and Kamenecka, {Theodore M.} and Pomrenze, {Matthew B.} and Messing, {Robert O.}",
year = "2020",
month = "1",
day = "1",
doi = "10.1038/s41386-019-0475-8",
language = "English (US)",
volume = "45",
pages = "301--308",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Promoting activity of (α4)3(β2)2 nicotinic cholinergic receptors reduces ethanol consumption

AU - Wang, Jingyi

AU - Blasio, Angelo

AU - Chapman, Holly L.

AU - Doebelin, Christelle

AU - Liaw, Victor

AU - Kuryatov, Alexander

AU - Giovanetti, Simone M.

AU - Lindstrom, Jon

AU - Lin, Li

AU - Cameron, Michael D.

AU - Kamenecka, Theodore M.

AU - Pomrenze, Matthew B.

AU - Messing, Robert O.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - There is increasing interest in developing drugs that act at α4β2 nicotinic acetylcholine receptors (nAChRs) to treat alcohol use disorder. The smoking cessation agent varenicline, a partial agonist of α4β2 nAChRs, reduces alcohol intake, but its use can be limited by side effects at high therapeutic doses. There are two stoichiometric forms of α4β2 nAChRs, (α4)3(β2)2 and (α4)2(β2)3. Here we investigated the hypothesis that NS9283, a positive allosteric modulator selective for the (α4)3(β2)2 form, reduces ethanol consumption. NS9283 increased the potency of varenicline to activate and desensitize (α4)3(β2)2 nAChRs in vitro without affecting other known targets of varenicline. In male and female C57BL/6J mice, NS9283 (10 mg/kg) reduced ethanol intake in a two-bottle choice, intermittent drinking procedure without affecting saccharin intake, ethanol-induced incoordination or ethanol-induced loss of the righting reflex. Subthreshold doses of NS9283 (2.5 mg/kg) plus varenicline (0.1 mg/kg) synergistically reduced ethanol intake in both sexes. Finally, despite having no aversive valence of its own, NS9283 enhanced ethanol-conditioned place aversion. We conclude that compounds targeting the (α4)3(β2)2 subtype of nAChRs can reduce alcohol consumption, and when administered in combination with varenicline, may allow use of lower varenicline doses to decrease varenicline side effects.

AB - There is increasing interest in developing drugs that act at α4β2 nicotinic acetylcholine receptors (nAChRs) to treat alcohol use disorder. The smoking cessation agent varenicline, a partial agonist of α4β2 nAChRs, reduces alcohol intake, but its use can be limited by side effects at high therapeutic doses. There are two stoichiometric forms of α4β2 nAChRs, (α4)3(β2)2 and (α4)2(β2)3. Here we investigated the hypothesis that NS9283, a positive allosteric modulator selective for the (α4)3(β2)2 form, reduces ethanol consumption. NS9283 increased the potency of varenicline to activate and desensitize (α4)3(β2)2 nAChRs in vitro without affecting other known targets of varenicline. In male and female C57BL/6J mice, NS9283 (10 mg/kg) reduced ethanol intake in a two-bottle choice, intermittent drinking procedure without affecting saccharin intake, ethanol-induced incoordination or ethanol-induced loss of the righting reflex. Subthreshold doses of NS9283 (2.5 mg/kg) plus varenicline (0.1 mg/kg) synergistically reduced ethanol intake in both sexes. Finally, despite having no aversive valence of its own, NS9283 enhanced ethanol-conditioned place aversion. We conclude that compounds targeting the (α4)3(β2)2 subtype of nAChRs can reduce alcohol consumption, and when administered in combination with varenicline, may allow use of lower varenicline doses to decrease varenicline side effects.

UR - http://www.scopus.com/inward/record.url?scp=85070842596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070842596&partnerID=8YFLogxK

U2 - 10.1038/s41386-019-0475-8

DO - 10.1038/s41386-019-0475-8

M3 - Article

AN - SCOPUS:85070842596

VL - 45

SP - 301

EP - 308

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 2

ER -